Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 13/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5441915 | 0.86 | GPR119 (0.55) | GPR119OPRD1OPRK1OPRM1 | |
| SCHEMBL4999880 | 0.86 | OPRD1 (0.54) | GPR119OPRD1OPRK1OPRM1 | |
| SCHEMBL14564242 | 0.82 | OPRD1 (0.73) | OPRD1OPRK1OPRM1 | |
| SCHEMBL5367295 | 0.82 | OPRD1 (0.57) | OPRD1OPRK1OPRM1 | |
| SCHEMBL5218154 | 0.82 | OPRD1 (0.59) | OPRD1OPRK1OPRM1 | |
| SCHEMBL1602493 | 0.82 | GPR119 (0.50) | GPR119OPRD1 | |
| SCHEMBL5954803 | 0.81 | OPRD1 (0.64) | OPRD1OPRK1OPRM1 | |
| SCHEMBL14543729 | 0.81 | OPRD1 (0.53) | GPR119OPRD1OPRK1OPRM1 | |
| SCHEMBL14572964 | 0.81 | OPRD1 (0.53) | GPR119OPRD1OPRK1OPRM1 | |
| SCHEMBL1603972 | 0.80 | OPRD1 (0.52) | GPR119OPRD1OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066655-A1 | Diarylmethylidene piperidine derivatives and their use as delta opiod receptor agonists | ATRAZENECA AB (SE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066655-A1 | Diarylmethylidene piperidine derivatives and their use as delta opiod receptor agonists | ATRAZENECA AB (SE) | 2007-03-22 | — | — | US | disclosed |
| EP-1626960-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES AND THEIR USE AS DELTA OPIOID RECEPTOR AGONISTS | AstraZeneca AB (SE) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004101520-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES AND THEIR USE AS DELTA OPIOD RECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066655-A1 | Diarylmethylidene piperidine derivatives and their use as delta opiod receptor agonists | OPRD1, OPRM1, OPRL1 | GPR119 173/4885OPRD1 1/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.